Maze Therapeutics (MAZE) Common Equity (2024 - 2026)

Maze Therapeutics has reported Common Equity for 3 years, with the latest figure at $341.7 million in Q1 2026.

• Quarterly Common Equity rose 16.99% year-over-year to $341.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341.7 million (up 16.99% YoY) and the FY2025 annual result came in at $355.0 million, up 214.07% from the prior year.
• Common Equity declined to $341.7 million in Q1 2026 per MAZE's latest filing, from $355.0 million in the prior quarter.
• Over five years, Common Equity peaked at $379.4 million in Q3 2025 and troughed at -$403.7 million in Q1 2024.
• A 3-year average of $41.0 million and a median of $262.2 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity surged 233.35% in 2025, then climbed 16.99% in 2026.
• Over 3 years, Common Equity stood at -$311.2 million in 2024, then soared by 214.07% to $355.0 million in 2025, then retreated by 3.74% to $341.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $341.7 million, $355.0 million, and $379.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.